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zidovudine and nevirapine. It is a highly effective and widely 
used 3-in-1 combination, but unfortunately not available in 
South Africa as Aspen appears not yet to have applied for its 
registration with the Medicines Control Council (MCC).
When Aspen was asked in September 2006 whether it has 
applied to the MCC for registration of the generic combination 
of lamivudine, zidovudine and nevirapine, Gavin Wiggill, 
Product Manager for Aspen, provided an evasive equivocal 
statement from which it was unclear whether they had applied. 
If not, it is imperative that they do so immediately.
Research indicates that stavudine, used as part of the 
standard first-line regimen in the Department of Health’s HIV 
treatment guidelines, should be replaced by tenofovir, which 
is a potent, safe and well-tolerated ARV. Stavudine-related 
toxicity is one of the main reasons for discontinuation and/or 
changing the first-line regimen.
Few people on ARV treatment are accessing tenofovir in 
terms of the Medicines and Related Substances Act, as it is a 
time-consuming and onerous process to initiate that has to be 
reviewed every 6 months. Tenofovir is therefore effectively not 
available for treatment in public health clinics.
Both Gilead and Aspen pharmaceutical companies have 
applied for registration of tenofovir over the past few years 
but the MCC has yet to approve its registration, in spite of 
Aspen requesting fast-track review status for its registration 
in November 2005. On 24 September 2006 Aspen supplied 
additional information on tenofovir requested by the MCC, 
which has since indicated that tenofovir may possibly be 
registered by early 2007.
In a recent issue of the Sunday Times1 Mandisa Hela, the MCC 
registrar, admitted that there is a drug registration backlog, 
with an average registration time of between 2 and 3 years for 
new drugs (including ARVs) entering the South African market. 
Experts working for the MCC indicate that this is largely owing 
to the exodus of skilled staff and increasing numbers of new 
drug applications. Reviews and evaluations of new drugs for 
registration are mostly outsourced to busy academics. The MCC 
therefore appears to be badly resourced and unable to cope 
with its mandate. Hela claimed that applications for registration 
of ARVs were automatically fast-tracked, but declined to 
comment on the pending tenofovir application saying ‘that is 
confidential information’.  
The MCC should review new drugs that are fast-tracked 
by first checking if the FDA and European Union (EU) have 
approved them. If so, the MCC should only check if there are 
any issues specific to South Africa that merit concern and then 
immediately register them. Atripla was approved in less than 3 
months in the USA under the FDA’s fast-track programme, and 
was made available within days following its approval. In spite 
of this good news about the availability of Atripla in the USA, it 
may take a long time before it becomes available in South Africa 
given the tardiness of the MCC in registering new medications, 
including ARVs. 
Given the extent of the HIV/AIDS pandemic in South Africa, 
it is essential that the MCC facilitate the registration of these 
life-extending medications as rapidly as possible. The MCC 
should encourage pharmaceutical companies to apply for the 
registration of new ARVs as soon as they become available and 
ensure that the fast-track registration process is significantly 
improved to make these life-extending medications available 
much sooner. 
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Child abuse and our society
To the Editor: What do we as society do to combat the threat of 
trauma, crime and violence? Approximately half our population 
are children, the most vulnerable members of society. Physical, 
emotional and sexual abuse among the latter has reached 
epidemic proportions, with approximately 25 000 sexual 
offences reported to the South African Police each year. Since 
approximately only 1 in 9 rapes are reported to the police we 
can assume that the annual number of sexually abused children 
is around 225 000. Over the last 10 years we at Red Cross War 
Memorial Children’s Hospital have treated approximately 1 000 
children under 12 years of age for rape.
What factors in our society contribute to this crime against 
our children?
1. The perpetrator is usually not a sinister stranger, but rather 
a well-known friend, family member or breadwinner.1 
2. In nearly all rape cases, there are important power roles. 
The perpetrator often has considerable physical, emotional, 
social or economic power over the victim, making sexual 
assault much more likely, especially since in 99% of all cases 
the perpetrator is male. These factors make it very difficult for 
the victim to disclose or report the crime. Nearly all sexually 
abused children do not disclose because they have been 
threatened, often with death. 
3. Disclosure of the sexual abuse causes significant distress 
for the child and his/her family, and disrupts the home 
environment. Medical examination, hospital admission, contact 
with social workers and medical staff, antiretroviral therapy 
and policemen investigating the assault are all major disruptive 
forces for any rape victim, in particular in the life of a young 
child. The family often takes enormous strain trying to stay 
together and not disintegrate. 
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4. South African society still has archaic and paternalistic 
patterns. The legal system appears to be failing the victims of 
sexual abuse. Adults must take responsibility for not using 
children and adolescents to satisfy their own needs. 
5. Sexual crimes are endemic in South Africa and it is not 
uncommon for women to have experienced multiple rapes 
before they reach adulthood. Have we become so desensitised 
that even in the legal proceedings sexual abuse is accepted as 
the norm?
We urge government to finalise the New Sexual Offences 
Bill. It redefines rape to include male victims and penetration 
of body orifices with non-sexual organs. It also sets the age 
of consent for all forms of sexual activity at 16 years for boys 
and girls. Children under the age of 12 are confirmed to be 
incapable of consenting to sex, but the Bill includes a qualified 
decriminalisation of sexual experimentation where this 
occurs between children aged 12 - 15 years, provided that the 
difference in age is not more than 2 years.
It is widely acknowledged that a ‘cycle of abuse’ exists. A 
main factor in becoming a child sexual perpetrator is having 
been sexually abused as a child. Therefore the apparent increase 
in number of sexual assaults on children is of even greater 
concern, as this is likely to drive a cycle of ever-increasing 
abuse.
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The South African Hypertension 
Guideline 2006 is evidence-based and 
not cost-effective – a rebuttal
To the Editor: Gaziano1 criticises the South African 
Hypertension (SAH) Guideline 20062 for being evidence-based 
but not cost-effective. He argues that global cardiovascular 
(CVS) risk assessment is important in making informative 
cost-effective treatment decisions. He gives examples that cost 
of treatment may range from US$20 000 per life-year saved to 
US$2 000 000, depending on the underlying global CVS risk. He 
argues that the SAH Guideline is too imprecise to assess CVS 
risk, and that patients at high risk may be denied treatment 
and patients at low risk may be treated inappropriately. For 
example, Gaziano argues that a patient with blood pressure 
(BP) below 140/90 mmHg may have an absolute risk between 
1% and 25%, which is too large to make effective decisions. 
Additionally, a significant amount of information can be lost 
by creating a change from one risk category to the next by 
the presence of 1 - 2 major risk factors, many of which are 
dichoctomised. 
It is very unfortunate that the SAMJ did not give the SAH 
Guideline Committee the opportunity to respond to Gaziano’s 
criticism in the same issue of the journal. The Committee gave 
considerable thought to both cost-effective and evidence-based 
guidelines. There was complete agreement that a CVS risk-
assessment strategy should be adopted to optimise resources 
to patients at higher risk. However, there was considerable 
debate with regard to whether the Committee should adopt 
the global CVS risk assessment or an absolute risk assessment. 
It was decided to base our policy on the absolute risk table 
of the ESH/ESC guidelines,3 mainly for practical reasons of 
implementation in the primary care setting. Gaziano himself 
states that ‘Guidelines must focus on the absolute or global 
clinical risk instead of the individual risk factors approaches in order 
to achieve an overall cost-effective reduction of disease.’1
Gaziano is indeed correct that the actual absolute risks 
are not stated in the Guideline, and this is an omission. Low, 
medium, high and very high risk give an absolute risk of CVS 
event in the next 10 years of < 15%, 15 - 20%, 20 - 30% and > 
30% based on Framingham data, and absolute risk of CVS 
death of < 4%, 4 - 5%, 5 - 8%, and > 8% based on the SCORE 
charts respectively.3 
Gaziano suggests that a 45-year-old male with no risk factors 
has a 2% chance of developing a CVS event in the next 10 
years and will ultimately require therapy according to the SAH 
Guideline, whereas a 55-year-old smoker with a low-density 
lipoprotein/high-density lipoprotein (LDL/HDL) cholesterol 
ratio of 6, and BP 139/84 mmHg, would not be treated 
according to the Guideline because he is at low risk, whereas 
his actual risk is 25% in the next 10 years. Let us examine these 
examples more carefully.
The first patient is clearly at low CVS risk, and there is 
agreement between Gaziano and the SAH risk table. The SAH 
Guideline recommends that the patient undergo lifestyle 
changes for the next 6 - 12 months and then requires drug 
treatment if the BP level remains above 140/90 mmHg. Gaziano 
is at issue with this policy as it is not cost-effective. It is purely 
speculative whether this patient will indeed require drug 
treatment. Most clinicians recognise that this patient is most 
likely to have white-coat hypertension because of the lack of 
risk factors and target organ damage. Repeated monitoring, 
which results in habituation to BP measurement, or self- or 
ambulatory BP monitoring, may reveal a quite normal BP 
profile in time. Additionally, lifestyle changes may also be 
helpful. Furthermore, if BP is still not controlled after 12 
months, this patient is likely to be treated with a low-dose 
thiazide plus angiotensin-converting enzyme (ACE) inhibitor. 
The current cost in the state sector is R3.33 per month. Based 
on the risk table published by Gaziano,1 the number needed to 
treat for 10 years to prevent 1 event is 33 and the direct drug 
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